scholarly journals Evolution from electrophysiologic to hemodynamic monitoring: the story of left atrial and pulmonary artery pressure monitors

2015 ◽  
Vol 6 ◽  
Author(s):  
Deirdre M. Mooney ◽  
Erik Fung ◽  
Rahul N. Doshi ◽  
David M. Shavelle
2000 ◽  
Vol 85 (8) ◽  
pp. 986-991 ◽  
Author(s):  
Jong-Won Ha ◽  
Namsik Chung ◽  
Yangsoo Jang ◽  
Woong-Chul Kang ◽  
Seok-Min Kang ◽  
...  

2010 ◽  
Vol 29 (9) ◽  
pp. 957-964 ◽  
Author(s):  
Theodoros Dimitroulas ◽  
Georgios Giannakoulas ◽  
Klio Papadopoulou ◽  
Tilemahos Sfetsios ◽  
Haralambos Karvounis ◽  
...  

2019 ◽  
Vol 11 (2) ◽  
pp. 147-151
Author(s):  
Muhammed Abdul Quaium Chowdhury ◽  
Mohammad Fazle Maruf ◽  
Minhazur Rahman ◽  
Subir Barua ◽  
Mamunur Rahman ◽  
...  

Background: Mitral stenosis is often present with pulmonary hypertension. Closed Mitral Commissurotomy (CMC) is a treatment of choice for severe mitral stenosis. In this study, we examined the per-operative changes of pulmonary artery pressure following opening of stenosed mitral valve. Methods: All these CMCs were performed routinely through the left antero-lateral thoracotomy (4th intercostal space) and dilatation was done by metallic Tubb’s Dilator. Peroperative left atrial and Pulminary Arterial pressures were measured before and after dilatation. Results: 15 patients had undergone CMC. Following CMC, per-operative mean Pulmonary artery pressure was reduced from 45.5±7.1 mm of Hg to 39.0±8.8 mm of Hg (p=0.043). Mean left atrial pressure reduced from 35.9±5.6 mm of Hg to 30.0±9.1 mm of Hg (p = 0.049). At three months follow up after closed mitral commissurotomy mitral valve area at echocardiography was found 2.29±0.18 cm2. There was no case of death after closed mitral commissurotomy. Mild mitral regurgitation occurred in 1 patient. Conclusion: We conclude that there is immediate significant reduction of pulmonary Artery pressure following closed mitral commissurotomy. This reduction is apparently comparable with a similar reduction of left atrial pressure. Cardiovasc. j. 2019; 11(2): 147-151


1987 ◽  
Vol 13 (1) ◽  
pp. 42-43
Author(s):  
Adeniyi O. Molajo Mrcp ◽  
Shirley R. Remington ◽  
William F. Thomas ◽  
Abdul K. Deiraniya

2018 ◽  
Vol 156 (3) ◽  
pp. 1161-1163
Author(s):  
Michael G. Katz ◽  
Anthony S. Fargnoli ◽  
Yassine Sassi ◽  
Roger J. Hajjar ◽  
Lahouaria Hadri

2020 ◽  
Vol 43 (9) ◽  
pp. 600-605 ◽  
Author(s):  
Yuichiro Kado ◽  
Takuma Miyamoto ◽  
David J Horvath ◽  
Shengqiang Gao ◽  
Kiyotaka Fukamachi ◽  
...  

This study aimed to evaluate a newly designed circulatory mock loop intended to model cardiac and circulatory hemodynamics for mechanical circulatory support device testing. The mock loop was built with dedicated ports suitable for attaching assist devices in various configurations. This biventricular mock loop uses two pneumatic pumps (Abiomed AB5000™, Danvers, MA, USA) driven by a dual-output driver (Thoratec Model 2600, Pleasanton, CA, USA). The drive pressures can be individually modified to simulate a healthy heart and left and/or right heart failure conditions, and variable compliance and fluid volume allow for additional customization. The loop output for a healthy heart was tested at 4.2 L/min with left and right atrial pressures of 1 and 5 mm Hg, respectively; a mean aortic pressure of 93 mm Hg; and pulmonary artery pressure of 17 mm Hg. Under conditions of left heart failure, these values were reduced to 2.1 L/min output, left atrial pressure = 28 mm Hg, right atrial pressure = 3 mm Hg, aortic pressure = 58 mm Hg, and pulmonary artery pressure = 35 mm Hg. Right heart failure resulted in the reverse balance: left atrial pressure = 0 mm Hg, right atrial pressure = 30 mm Hg, aortic pressure = 100 mm Hg, and pulmonary artery pressure = 13 mm Hg with a flow of 3.9 L/min. For biventricular heart failure, flow was decreased to 1.6 L/min, left atrial pressure = 13 mm Hg, right atrial pressure = 13 mm Hg, aortic pressure = 52 mm Hg, and pulmonary artery pressure = 18 mm Hg. This mock loop could become a reliable bench tool to simulate a range of heart failure conditions.


2021 ◽  
Vol 14 (6) ◽  
Author(s):  
Ersilia M. DeFilippis ◽  
John Henderson ◽  
Kelly M. Axsom ◽  
Maria Rosa Costanzo ◽  
Philip B. Adamson ◽  
...  

Background: Response to pharmacological and device-based therapy for heart failure (HF) may vary by sex. We examined sex differences in response to ambulatory hemodynamic monitoring in clinical practice using the CardioMEMS PAS (Post-Approval Study). Methods: The CardioMEMS PAS was a prospective, single-arm, multicenter, open-label study of 1200 adults with New York Heart Association class III HF and at least 1 HF hospitalization (HFH) within 12 months who underwent pulmonary artery pressure sensor implantation between 2014 and 2017. Changes in pulmonary artery pressure over time were stratified by ejection fraction <40% and sex. Clinical outcomes including HFH rate at 12 months, 1-year mortality, and quality of life were examined in women and men. Results: Four hundred fifty-two women (38% of total) enrolled in the PAS were less likely to be White (78% versus 86%) and more likely to have nonischemic cardiomyopathy (44% versus 34%) and had significantly higher SBP (132 versus 124 mm Hg), mean ejection fraction (44% versus 36%), and pulmonary vascular resistance (3.2 versus 2.6 WU) than men ( P <0.001 for all). There were similar reductions in pulmonary artery pressure from baseline to 12 months in both men and women for the whole cohort and for subgroups with HF with reduced ejection fraction and HF with preserved ejection fraction. Both sexes experienced significant decreases in HFH over 12 months (men: HR, 0.46 [95% CI, 0.40–0.52]; women: HR, 0.39 [95% CI, 0.33–0.46]). In adjusted models, there were no significant differences in change in HFH between men and women (interaction P =0.13) or all-cause mortality at 1 year (adjusted HR, 1.25 [95% CI, 0.88–1.77]). Conclusions: Women and men enrolled in the CardioMEMS PAS had similar reductions from baseline in pulmonary artery pressure over 1 year and experienced similar reductions in HFH. Hemodynamic monitoring provides similar benefit with regard to HF events in both women and men. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02279888.


Sign in / Sign up

Export Citation Format

Share Document